Richard Bethell
Chief Executive Officer chez Svenska Vaccinfabriken Produktion AB
Profil
Richard Bethell is currently the Chief Executive Officer at Svenska Vaccinfabriken Produktion AB and also holds the position of Chief Development Officer at STipe Therapeutics ApS.
Previously, he worked as the Chief Executive Officer at Karolinska Development AB, Executive Vice President-Discovery Research at Medivir AB, Head-Biological Sciences at Boehringer Ingelheim (Canada) Ltd., and Head-Therapeutic Research at Shire Sweden AB.
He holds a doctorate degree from the University of Oxford and a graduate degree from the University of Cambridge.
Postes actifs de Richard Bethell
| Sociétés | Poste | Début |
|---|---|---|
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Corporate Officer/Principal | - |
Svenska Vaccinfabriken Produktion AB
 Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Chief Executive Officer | 11/01/2022 |
Anciens postes connus de Richard Bethell
| Sociétés | Poste | Fin |
|---|---|---|
| KAROLINSKA DEVELOPMENT AB | Chief Executive Officer | - |
Boehringer Ingelheim (Canada) Ltd.
 Boehringer Ingelheim (Canada) Ltd. BiotechnologyHealth Technology Boehringer Ingelheim (Canada) Ltd. engages in the research and development of new drugs and medicines for the treatment of respiratory diseases. The firm offers therapeutic options for diseases and conditions, such as chronic obstructive pulmonary disease, high blood pressure, stroke, depression, benign prostatic hyperplasia, Parkinson's disease, virology, stroke prevention in atrial fibrillation, and diabetes. The company was founded in 1972 and is headquartered in Burlington, Canada. | Corporate Officer/Principal | - |
| Shire Sweden AB | Corporate Officer/Principal | - |
| MEDIVIR AB | Chief Tech/Sci/R&D Officer | - |
Formation de Richard Bethell
| University of Oxford | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MEDIVIR AB | Health Technology |
| KAROLINSKA DEVELOPMENT AB | Finance |
| Entreprise privées | 4 |
|---|---|
Boehringer Ingelheim (Canada) Ltd.
Boehringer Ingelheim (Canada) Ltd. BiotechnologyHealth Technology Boehringer Ingelheim (Canada) Ltd. engages in the research and development of new drugs and medicines for the treatment of respiratory diseases. The firm offers therapeutic options for diseases and conditions, such as chronic obstructive pulmonary disease, high blood pressure, stroke, depression, benign prostatic hyperplasia, Parkinson's disease, virology, stroke prevention in atrial fibrillation, and diabetes. The company was founded in 1972 and is headquartered in Burlington, Canada. | Health Technology |
Svenska Vaccinfabriken Produktion AB
Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Health Technology |
| Shire Sweden AB | |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Health Technology |
